Moxifloxacin hydrochloride 0.3 mg mL⁻¹ in 0.8 % sodium chloride (saline)
(also sold as “moxifloxacin in saline” or “Moxifloxacin IV solution” – the 0.8 % saline acts as the diluent and helps maintain isotonicity)
1. What it is & how it works
- Drug class: Fluoroquinolone antibiotic
- Mechanism: Inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication and transcription.
- Spectrum: Broad‑spectrum Gram‑positive and Gram‑negative coverage, including many respiratory pathogens, skin/soft‑tissue organisms, and Streptococcus spp.
2. Approved indications (US FDA/EMA)
| Infection |
Typical patient group |
Typical dose |
| Community‑acquired pneumonia (CAP) |
Adults & older adults |
400 mg IV once daily (or 400 mg PO once daily) |
| Bacterial skin & soft‑tissue infections |
Adults |
400 mg IV once daily |
| Complicated urinary tract infection (cUTI) |
Adults |
400 mg IV once daily |
| Acute exacerbation of chronic bronchitis (in patients not suitable for oral therapy) |
Adults |
400 mg IV once daily |
(Refer to local prescribing information for exact dosing in pediatric or special‑case scenarios.)
3. How to use the IV formulation
| Step |
Detail |
| Reconstitution |
The vial contains a lyophilized powder. Reconstitute with 1 mL of the 0.8 % NaCl solution before adding the 0.8 % NaCl diluent. |
| Dilution |
Add 10 mL of 0.8 % NaCl to obtain a 0.3 mg mL⁻¹ concentration. (Adjust volume if different concentration is required—always follow product label.) |
| Administration |
Infuse over 30–60 min via IV route. The solution is clear, colourless, and free of particulate matter. |
| Storage |
Store in the original plastic vial at 2–8 °C. Do not store in glass bottles or containers that could react with the drug. Once reconstituted, keep refrigerated and use within 24 h (check local guidelines). |
| Compatibility |
Compatible with normal saline, Ringer’s lactate, and most routine IV fluids. Avoid mixing with strong oxidizing agents (e.g., hydrogen peroxide). |
4. Common adverse reactions
| System |
Common events (≤1 %) |
| GI |
Nausea, vomiting, diarrhea, abdominal pain |
| Central nervous system |
Headache, dizziness, insomnia, tinnitus, seizures (rare) |
| Cardiovascular |
QT‑interval prolongation, palpitations |
| Musculoskeletal |
Tendonitis, tendon rupture (especially in older adults, concurrent corticosteroids, or renal impairment) |
| Hepatobiliary |
Elevated transaminases (rare) |
| Other |
Rash, hypersensitivity reactions, phototoxicity |
5. Contraindications & Precautions
| Category |
Notes |
| Hypersensitivity |
Contraindicated in patients with a known allergy to moxifloxacin or other quinolones. |
| Pregnancy/Breastfeeding |
Category C. Use only if benefits outweigh risks. |
| Pediatric use |
Generally not recommended for children <12 yrs except in special circumstances; use with caution in 12–17 yrs. |
| Renal impairment |
Dose adjustment required. For CrCl 30–49 mL min⁻¹, reduce dose to 200 mg IV once daily. |
| Hepatic impairment |
No dose adjustment needed for mild‑moderate liver disease. |
| Seizure disorders |
May lower seizure threshold. |
| QT‑prolonging drugs |
Monitor ECG; avoid with drugs like cisapride, terfenadine, or azithromycin. |
| Gastrointestinal ulcer disease |
Avoid use in severe ulcers due to risk of perforation. |
6. Drug interactions
| Drug class |
Interaction |
| Other fluoroquinolones |
Additive neurotoxic effects. |
| Corticosteroids |
↑ risk of tendon rupture. |
| NSAIDs |
↑ risk of tendon rupture. |
| Azithromycin, ciprofloxacin, levofloxacin |
↑ QT‑interval prolongation. |
| Diazepam |
↑ risk of seizures. |
| St. John’s Wort |
↑ moxifloxacin metabolism (lower levels). |
| H₂‑blockers / PPIs |
↓ absorption of oral moxifloxacin (irrelevant for IV). |
(Always review the patient’s full medication list.)
7. Special instructions for the plastic container
- Integrity: Use only the supplied plastic vial; do not transfer to glass or other containers that may leach plasticizers.
- Temperature: Keep refrigerated (2–8 °C). Do not freeze.
- Light exposure: Store in a light‑protected cabinet; light can degrade the drug.
- End‑of‑use: Dispose of the container in accordance with your institution’s hazardous waste guidelines (do not flush down the toilet).
8. When to seek medical help
- Signs of hypersensitivity: rash, itching, swelling, respiratory difficulty.
- Tendon pain or swelling (especially in the Achilles or rotator cuff).
- Severe abdominal pain, vomiting, or signs of sepsis.
- Any neurological symptoms (confusion, seizures).
9. Quick reference (adult dosing)
| Condition |
Dose |
Frequency |
Notes |
| CAP |
400 mg IV |
Once daily |
Switch to oral 400 mg PO once daily when clinically stable. |
| Skin/Soft‑tissue |
400 mg IV |
Once daily |
Continue 3–10 days depending on severity. |
| cUTI |
400 mg IV |
Once daily |
Continue 7–14 days; monitor renal function. |
| Acute exacerbation of bronchitis (IV) |
400 mg IV |
Once daily |
Transition to oral if improvement. |
(Always confirm with your local formularies or prescribing information.)
Bottom line
Moxifloxacin IV in 0.8 % saline is a versatile, broad‑spectrum fluoroquinolone used for serious infections in adults. It should be reconstituted, diluted, and infused per the above guidelines, and used with caution in patients at risk for tendon injury, QT‑prolongation, or renal impairment. Store it in its plastic vial, keep it cold and protected from light, and dispose of it safely after use.
If you have a specific clinical question (e.g., dosing in renal failure, interactions with a particular drug, or pediatric use), let me know!